Moreover, we demonstrated that while mutant Jak2 can cooperate with Crlf2 to drive development of leukemia in mice, genetic depletion or pharmacological inhibition of Jak2 served merely to delay proliferation of the leukemias, resulting in a modest therapeutic response in vivo. Here, JAK2 is linked to leukemia.